The solid-state laser advantage

Article

Clinical outcomes of laser epithelial keratomileusis using a 213 nm wavelength solid-state laser

The 213 nm wavelength generated by solid state platforms (e.g., Pulzar Z1, CustomVis, Perth, Australia) demonstrates superior transmissibility through water compared to 193 nm, so is less sensitive to levels of corneal hydration, and may reduce the variability in refractive outcomes linked with corneal hydration; corneas that become dehydrated during excimer laser treatment are often overcorrected, while superhydration is linked with undercorrection.3 Furthermore, the absence of dangerous gas eliminates sudden noise, and patient anxiety, as laser operation commences, while maintenance costs are also substantially reduced.

Clinical outcomes

Earlier this year, we reported outcomes from a cohort of patients undergoing laser epithelial keratomileusis (LASEK) performed by the same surgeon using the CustomVis solid-state refractive laser.8 The CustomVis system generates a 213 nm wavelength by transmission of a 1064 nm Nd:YAG laser beam through three non-linear crystals. The 0.6 mm diameter quasi-Gaussian-shaped flying spot has a 300 Hz pulse repetition rate, and the system employs three methods of eye tracking technology: a limbus-based eye tracker with a closed-loop response of 1-kHz, a video eye tracker to facilitate a higher level of accuracy and a video gaze tracker, confirming patient fixation.

The cohort included 245 eyes of 134 patients with a mean age of 41.0 ± 12.2 years. Patients had a broad range of preoperative refractive errors, with sphere values ranging from –9.50 to +6.50 D (mean –1.59 ± 3.22 D) and astigmatism between 0 and –5.50 D (mean –0.98 ± 1.17 D). Postoperative follow-up visits were scheduled at 2 and 6 months.

LASEK surgery performed on this substantial cohort was shown to be effective, safe and stable over the follow-up period. Over 95% of eyes maintained the same best corrected distance visual acuity (CDVA) postoperatively, or gained a line, and the mean postoperative spherical equivalent refractive error (SE) was stable between the 2 month (–0.01 ± 0.57 D) and 6 month (–0.01 ± 0.55 D) visits. Treatment was accurate for both myopes and hyperopes, with mean SEs at 6 months of +0.02 ± 0.27 D and 0.21 ± 0.66 D, respectively.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.